Association of Selective Serotonin Reuptake Inhibitor Use After Intracerebral Hemorrhage With Hemorrhage Recurrence and Depression Severity | Zendy

Patryk Kubiszewski | Zendy; Lansing Sugita | Zendy; Christina Kourkoulis | Zendy; Zora DiPucchio | Zendy; Kristin Schwab | Zendy; Christopher D. Anderson | Zendy; M. Edip Gurol | Zendy; Steven M. Greenberg | Zendy; Anand Viswanathan | Zendy; Jonathan Rosand | Zendy; Alessandro Biffi | Zendy

Open Access

Association of Selective Serotonin Reuptake Inhibitor Use After Intracerebral Hemorrhage With Hemorrhage Recurrence and Depression Severity

Author(s) -

Patryk Kubiszewski,

Lansing Sugita,

Christina Kourkoulis,

Zora DiPucchio,

Kristin Schwab,

Christopher D. Anderson,

M. Edip Gurol,

Steven M. Greenberg,

Anand Viswanathan,

Jonathan Rosand,

Alessandro Biffi

Publication year - 2020

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2020.3142

Subject(s) - medicine , intracerebral hemorrhage , depression (economics) , interquartile range , serotonin reuptake inhibitor , stroke (engine) , population , cohort , pediatrics , antidepressant , subarachnoid hemorrhage , economics , macroeconomics , mechanical engineering , environmental health , hippocampus , engineering

Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat poststroke depression but are associated with increased incidence of first-ever intracerebral hemorrhage (ICH) in the general population. The decision to treat ICH survivors with SSRIs must therefore balance potential risks of ICH recurrence with presumed benefits on depressive symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research